Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/01/20
End: 12/01/24
Due: 12/01/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma | NCT04997850 | Xinrui Zhu | user2@example.com | None | 2020-05-01 | 2024-12-01 | 2025-12-01 | - | - | 2025-07-14 |